Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hal-mre1
- Development stage
- Phase 1
- Lead developer
- HAL Allergy
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
HAL-MRE1 is a subcutaneous allergen immunotherapy being developed by HAL Allergy Group for the treatment of ragweed-induced allergic conditions. It is formulated as a liquid suspension containing modified allergens extracted from ragweed pollen adsorbed onto aluminum hydroxide. [6] As an allergen immunotherapy, it aims to modify the underlying cause of the allergy by administering controlled doses of the allergen, which helps the immune system to build tolerance and reduce the allergic response. [2] A first-in-human, Phase 1 clinical trial (NCT03758456) was initiated to evaluate its safety and tolerability in adults with ragweed-induced allergic rhinitis or rhinoconjunctivitis, with or without asthma. [6]
- Other names
- Ragweed pollen allergens (HAL Allergy)HAL-MRE1HAL-MRE-1HAL-MRE 1
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on hal-mre1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hal-mre1.